Novartis Aktie
WKN: 904278 / ISIN: CH0012005267
|
27.10.2026 06:59:54
|
Press Release: Novartis delivered sales growth -3-
at an upcoming medical congress.
Kisqali The six-year follow-up analysis of the Phase III NATALEE
(ribociclib) trial showed a clinically meaningful overall survival
(OS) benefit with Kisqali plus endocrine therapy (ET)
versus ET alone in the broadest HR+/HER2- early breast
cancer (eBC) population at high risk of recurrence,
reducing the risk of death by nearly 20%. Patients
had been off Kisqali treatment for a median of 38
months, with clinical benefit continuing to deepen
after treatment completion. The safety profile remained
consistent with previous analyses. Data were presented
at ESMO 2026.
LOU064 Novartis has discontinued the Phase III study of remibrutinib
(remibrutinib) in generalized myasthenia gravis (gMG) following a
futility analysis, which indicated the treatment was
unlikely to meet its efficacy objectives. No safety
concerns were identified, and there is no impact on
remibrutinib studies in other indications.
Selected Novartis completed the acquisition of Myricx Bio,
transactions strengthening the oncology pipeline with a new class
of antibody-drug conjugates (ADCs), including two
lead assets targeting B7-H3 and HER2, as well as a
broader payload platform with potential impact across
multiple solid tumor settings.
Novartis exercised its exclusive option to acquire
full global rights to Sironax's proprietary Brain
Delivery Module (BDM) platform, a next-generation
blood-brain barrier crossing technology with the potential
to transform the treatment of central nervous system
diseases.
Novartis entered into an exclusive global licensing
agreement with BoomRay Pharmaceuticals for an undisclosed
preclinical radioligand therapy asset, further strengthening
its radioligand therapy portfolio.
In October, Novartis entered into a strategic licensing
and option agreement with Abogen Biosciences to advance
RNA-encoded therapeutics, including an exclusive worldwide
license to ABO2203, a novel mRNA-encoded CD19xCD3
T-cell engager with the potential to transform the
treatment landscape for autoimmune diseases. The transaction
is subject to the completion of customary closing
conditions.
Capital structure and net debt
Retaining a good balance between investment in the business, a strong capital structure, and attractive shareholder returns remains a priority.
During the first nine months of 2026, Novartis repurchased 30.9 million shares for USD 4.7 billion on the SIX Swiss Exchange second trading line. These repurchases included 18.8 million shares (USD 2.8 billion) under the up-to USD 10 billion share buyback announced in July 2025 (with up to USD 4.9 billion still to be executed). In addition, 12.1 million shares (USD 1.8 billion) were repurchased to mitigate the anticipated full-year dilution related to participation plans of employees. Further, 2.0 million shares (USD 0.3 billion) were repurchased from employees. During the same period, USD 0.9 billion of equity-based compensation plan expenses were recognized to equity and 13.3 million shares were delivered to employees related to equity-based compensation plans from prior years. As a result, the total number of shares outstanding decreased by 19.6 million compared with December 31, 2025. These treasury share transactions resulted in an equity decrease of USD 4.1 billion and a cash outflow of USD 4.8 billion.
Net debt increased to USD 37.4 billion at September 30, 2026, compared with USD 21.9 billion at December 31, 2025. The increase was mainly due to the free cash flow of USD 14.0 billion being more than offset by the net cash outflow for M&A, intangible assets transactions and other acquisitions of USD 16.7 billion, the USD 9.1 billion annual dividend payment and cash outflows for treasury share transactions of USD 4.8 billion.
As of Q3 2026, the long-term credit rating for the company is Aa3 with Moody's Ratings and AA- with S&P Global Ratings.
2026 outlook
Barring unforeseen events; growth vs. prior year in
cc
Net sales Expected to grow low single-digit
Core operating income Expected to be in line to grow low single-digit
(from decline low single-digit)
Foreign exchange impact
If late-October exchange rates prevail for the remainder of 2026, the foreign exchange impact for the year would be positive 1 percentage point on net sales and positive 1 percentage point on core operating income. The estimated impact of exchange rates on our results is provided monthly on our website.
2027 Annual General Meeting
Nomination for election to the Board of Directors
The Novartis Board of Directors announced today that it is nominating Rajesh Jha for election to the Board. During a 36-year career at Microsoft, Mr. Jha held a series of senior leadership roles across software engineering, productivity platforms and enterprise technologies, and served on the company's Senior Leadership Team from 2016 until his retirement. Most recently, he served as Executive Vice President, Experiences + Devices, where he led the product teams for Microsoft 365, Office, Teams, Windows + Devices, and Dynamics, and played a key role in the integration of artificial intelligence across Microsoft's product portfolio. His extensive experience in technology, AI and large-scale digital platforms would add significantly to the Novartis Board of Directors.
Key figures(1)
Q3 Q3
2026 2025 % change 9M 2026 9M 2025 % change
USD USD USD USD
m(2) m(2) USD cc m(2) m(2) USD cc
------ ------ ---- ---- ------- ------- ---- ----
Net sales 14 522 13 909 4 4 42 043 41 196 2 0
------ ------ ---- ---- ------- ------- ---- ----
Operating income 1 843 4 501 -59 -61 10 828 14 028 -23 -24
------ ------ ---- ---- ------- ------- ---- ----
As a % of sales 12.7 32.4 25.8 34.1
---------------------- ------ ------ ------- -------
Net income 1 196 3 930 -70 -71 7 609 11 563 -34 -35
------ ------ ---- ---- ------- ------- ---- ----
EPS (USD) 0.63 2.04 -69 -70 4.01 5.94 -32 -33
------ ------ ---- ---- ------- ------- ---- ----
Net cash flows from
operating activities 5 503 6 571 -16 15 061 16 880 -11
------ ------ ---- ------- ------- ----
Non-IFRS measures
Free cash flow 5 111 6 217 -18 14 002 15 941 -12
------ ------ ---- ------- ------- ----
Core operating income 6 036 5 460 11 10 16 873 16 960 -1 -2
------ ------ ---- ---- ------- ------- ---- ----
As a % of sales 41.6 39.3 40.1 41.2
---------------------- ------ ------ ------- -------
Core net income 4 655 4 330 8 6 13 027 13 522 -4 -5
------ ------ ---- ---- ------- ------- ---- ----
Core EPS (USD) 2.46 2.25 9 8 6.85 6.94 -1 -3
------ ------ ---- ---- ------- ------- ---- ----
1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 45 of the Condensed Interim Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. 2. USD millions unless indicated otherwise.
Detailed financial results accompanying this press release are included in the Condensed Interim Financial Report at the link below:
https://www.novartis.com/sites/novartis_com/files/q3-2026-interim-financial-report-en.pdf
Disclaimer
This communication contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as "expected," "anticipated," "can," "will," "continue," "ongoing," "growth," "launch," "expanding," "deliver," "accelerate," "guidance," "outlook," "priority," "potential," "momentum," "on track," "pipeline," "evidence," "progress," "emerging," or similar expressions, or by express or implied discussions regarding: potential new products, potential new indications for existing products, potential product launches or potential future revenues from any such products; or results of ongoing clinical trials; potential future, pending or announced transactions; potential future sales or earnings; strategy, plans, expectations or intentions, including discussions regarding our continued investment into new R&D capabilities and manufacturing; our capital structure. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in
(MORE TO FOLLOW) Dow Jones Newswires
October 27, 2026 02:00 ET (06:00 GMT)
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novartis AG
|
20.11.26 |
SIX-Handel SMI beendet den Handel im Minus (finanzen.at) | |
|
20.11.26 |
Freitagshandel in Zürich: SLI schwächelt nachmittags (finanzen.at) | |
|
20.11.26 |
SIX-Handel So entwickelt sich der SMI am Nachmittag (finanzen.at) | |
|
20.11.26 |
Schwacher Wochentag in Zürich: SMI verbucht am Freitagmittag Abschläge (finanzen.at) | |
|
20.11.26 |
Angespannte Stimmung in Zürich: SLI zeigt sich zum Handelsstart schwächer (finanzen.at) | |
|
20.11.26 |
Schwache Performance in Zürich: SMI zum Start in der Verlustzone (finanzen.at) | |
|
19.11.26 |
Verluste in Zürich: SMI verliert zum Ende des Donnerstagshandels (finanzen.at) | |
|
19.11.26 |
Börse Zürich in Rot: SLI legt zum Handelsende den Rückwärtsgang ein (finanzen.at) |
Analysen zu Novartis AG
| 20.11.26 | Novartis Neutral | UBS AG | |
| 19.11.26 | Novartis Sector Perform | RBC Capital Markets | |
| 19.11.26 | Novartis Hold | Jefferies & Company Inc. | |
| 11.11.26 | Novartis Hold | Jefferies & Company Inc. | |
| 11.11.26 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) |
Aktien in diesem Artikel
| Novartis AG | 136,80 | -0,75% |
|
| Novartis AG (Spons. ADRS) | 137,00 | 0,00% |
|